Dr Reddy’s Q1 Profit Plunges 69% to ₹435.6 Crore on Lower Revenue

The Weight of Transition and Setbacks

Dr. Reddy’s Laboratories reported a steep 69% year-on-year drop in its consolidated net profit to ₹435.6 crore for the June-end quarter, falling well short of broader market expectations. This sharp profit contraction was primarily driven by lower sales of the blockbuster cancer drug lenalidomide, the generic version of Revlimid, as the company moved past its peak exclusivity revenue windows. Total revenue from operations slipped 5.6% year-on-year to ₹8,099.8 crore, weighed down heavily by a 35% slump in North American revenues. While domestic and various emerging markets posted solid double-digit growth, the overall top line faced severe headwinds from shifting product mixes and regional market transitions. Analysts noted that the tapering off of high-margin legacy products left the company vulnerable to immediate earnings volatility.

The Semaglutide Provision and Quality Hurdles

Adding heavily to these top-line pressures, the pharmaceutical major took an unexpected financial hit from its high-priority GLP-1 portfolio. Certain batches of active pharmaceutical ingredients for the weight-loss and diabetes drug semaglutide were found to be out of specification due to unexpected quality issues, forcing the company to temporarily halt shipments and delay its much-anticipated commercial scale-up. Consequently, Dr. Reddy’s booked a substantial one-time provision of ₹239.7 crore toward affected inventory and associated regulatory compliance costs. This single provision shaved roughly three percentage points off gross profit, EBITDA, and profit-before-tax margins, compounding margin erosion that was already being driven by elevated solvent and freight expenses tied to global supply chain disruptions.

Core Resilience and Future Pipeline Focus

Despite the challenging quarter marked by regulatory hurdles and the post-lenalidomide cliff, management emphasized that the underlying base business remains remarkably robust, delivering healthy double-digit growth across key geographies like India, Europe, and select emerging markets. Leadership noted that root causes for the semaglutide API issues are actively being resolved through rigorous protocol upgrades, with commercial supply expected to resume in the coming months. Moving forward, Dr. Reddy’s intends to lean heavily on disciplined operational execution, a solid net cash surplus exceeding ₹3,058 crore, and its rapidly expanding pipeline in complex peptides, biosimilars, and differentiated generics to anchor its long-term growth trajectory and reassure jittery investors.